• To evaluate the theoretical therapeutic impact (in terms of CHIMIOPROPHYLAXIE antituberculous theoretically managed) of the tracking of tuberculosis-latent by QTF-TB Gold IT® or T-SPOT.TB among patients HIV. [ Time Frame: J0 ] [ Designated as safety issue: Yes ]
  

Principal outcome:

-Theoretic therapeutic impact evaluation of the use of IGRAS for diagnosis of LTBI in HIV-infected patients .

Secondary outcomes:

• Medico-economic impact of replacement of TST by IGRAs in LTBI screening in HIV infected patients.
• Concordance of IGRAs results with TST
• Concordance between IGRAs.
• Concordance between IGRAs in accordance to CD4 number(< 100, 100 à 200, 200 à 300, > à 300/mm3).
• LTBI prevalence in the study group.
• Effective consequences of tests results on therapeutic outcome of the patients LTBI criteria and therapeutic recommendations
• One or 2 positive IGRAs test: LTBI recommended to be LTBI
• 1 negative IGRAs test and one undetermined : no LTBI
• 2 undetermined:
• No clinical risk and negative TST: no diagnosis, eventually new test at 3 months or after HAART onset.
• Clinical risk or TST> 10mm: LTBI recommended to be treated. Therapeutic outcome evaluation Effective consequences of IGRA's result on patients outcome at 6 months.

Analyzed criteria:

Therapeutic impact:

• Patients percentage with different therapeutic outcome based on usual recommendations
• Medico-economic impact
• Medico-economic impact of both tests as early and late cost - efficacy
• Statistics

Primary criteria:

• Percentage of patients for whom therapeutic would have been changed by IGRAs results compared to usual diagnosis strategy.

Secondary criteria:

• Concordance of IGRAs with TST
• Concordance between both IGRAs.
• Taille: 1000 patients

Timing:

-inclusions: 2 years